Welcome to our dedicated page for Biogen news (Ticker: BIIB), a resource for investors and traders seeking the latest updates and insights on Biogen stock.
Biogen Inc. (Nasdaq: BIIB) is a pioneering biotechnology company founded in 1978, dedicated to discovering, developing, and delivering innovative therapies for people living with serious neurological and neurodegenerative diseases. With a robust portfolio of medicines, Biogen is a global leader in the treatment of multiple sclerosis (MS) and has introduced the first and only approved treatment for spinal muscular atrophy (SMA). The company is also at the forefront of research for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).
Headquartered in Cambridge, Massachusetts, Biogen operates worldwide with research facilities in Zug, Switzerland, and state-of-the-art manufacturing plants in North Carolina and Denmark. The company employs approximately 7,000 people globally, emphasizing a collaborative and inclusive work environment.
Biogen's significant achievements include the development of revolutionary MS treatments such as Avonex, Plegridy, Tysabri, Tecfidera, and Vumerity. The company also markets Spinraza for SMA and Leqembi for Alzheimer’s disease, in collaboration with partners like Ionis and Eisai respectively. Biogen continues to expand its pipeline with promising candidates currently in various stages of clinical trials.
Recent developments have seen Biogen and Eisai submit a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for monthly maintenance dosing of Leqembi, aimed at treating Alzheimer's disease in its early stages. Furthermore, Biogen published its 2023 Corporate Responsibility Report, highlighting its commitment to sustainable practices and social responsibility across four key pillars.
In addition to its core operations, Biogen collaborates with companies like Delta Flight Products to improve travel experiences for passengers with reduced mobility. This initiative reflects Biogen’s broader mission to enhance the quality of life for individuals facing debilitating conditions.
Biogen's financial health is robust, with strategic mergers and acquisitions like the recent purchase of Human Immunology Biosciences for $1.15 billion, aiming to bolster its immunology pipeline. The company’s comprehensive approach to business involves balancing bold scientific endeavors with prudent financial management to ensure long-term growth and shareholder value.
For more information about Biogen's latest news and updates, visit www.biogen.com.
Biogen (NASDAQ: BIIB) announced new data highlighting the effectiveness and safety of its multiple sclerosis (MS) therapies at the MSVirtual2020 conference. Key findings from the Phase 3 study of VUMERITY® (diroximel fumarate) show improved gastrointestinal tolerability compared to TECFIDERA®. In two years, 90% of VUMERITY patients remained free from confirmed disability progression. Real-world studies indicate TYSABRI® (natalizumab) improved quality of life over Ocrevus®. Additionally, PLEGRIDY® and AVONEX® showed benefits in older patients with relapsing MS. Biogen is also advancing BIIB091, a BTK inhibitor for MS treatment.
Biogen (Nasdaq: BIIB) released findings from two real-world studies on health disparities in multiple sclerosis (MS) during MSVirtual2020. The research, from MS PATHS and NARCRMS, reveals significant socio-demographic disparities affecting Black and Hispanic individuals with MS, including higher unemployment and income differences compared to white counterparts. The studies also predict employment status based on disability assessments. Biogen's ongoing development of digital tools aims to enhance treatment decisions and improve patient outcomes.
Biogen Inc. (Nasdaq: BIIB) announced a $10 million investment in OneUnited Bank, the largest Black-owned bank in the U.S., aimed at supporting Black economic empowerment. This deposit represents a growing corporate focus on Black businesses and lenders. OneUnited Bank reports a 100% increase in interest since May 2020, attracting over 50,000 new customers and $50 million in deposits. Biogen's investment aligns with its Diversity, Equity, and Inclusion strategy and may help strengthen underrepresented minority businesses.
Biogen and Eisai announced that the FDA accepted the Biologics License Application (BLA) for aducanumab, an investigational Alzheimer’s treatment, granting it Priority Review. The PDUFA target action date is set for March 7, 2021. If approved, aducanumab would be the first therapy to significantly alter Alzheimer’s disease progression and demonstrate better outcomes through amyloid beta removal. This milestone is seen as a potential paradigm shift in treating dementia, addressing a critical public health issue.
Biogen (Nasdaq: BIIB) has entered a collaboration with Denali Therapeutics to co-develop and co-commercialize Denali's LRRK2 inhibitors for Parkinson's disease. The agreement includes a $560 million upfront payment and a $465 million equity investment from Biogen, along with potential milestone payments exceeding $1 billion. Biogen will share development costs (60% Biogen, 40% Denali) and split profits in the U.S. and China (50/50). Biogen also gains rights to two additional programs using Denali's Transport Vehicle technology for neurodegenerative diseases.
Biogen (Nasdaq: BIIB) will present multiple data from its Alzheimer’s disease (AD) clinical development portfolio at the Alzheimer’s Association International Conference (AAIC) online from July 27-31. Highlights include an encore platform presentation of aducanumab's Phase 3 EMERGE and ENGAGE study results on July 29. Additional presentations will cover gosuranemab (BIIB092) and other investigational therapies aimed at improving AD diagnosis and treatment. The event will enhance understanding of patient needs and healthcare capabilities for AD management.
Biogen Inc. (Nasdaq: BIIB) has appointed Michael McDonnell as Executive Vice President and Chief Financial Officer, effective August 15, 2020. Previously CFO at IQVIA, McDonnell will oversee global finance, IT, and investor relations at Biogen. He succeeds Jeffrey Capello, who will assist in the transition before departing on September 15, 2020. CEO Michel Vounatsos expressed confidence in McDonnell’s strategic financial expertise, highlighting the importance of his role amid Biogen's potential breakthroughs in neuroscience.
Biogen (Nasdaq: BIIB) announced plans for a global Phase 4 clinical study, RESPOND, to assess the efficacy and safety of SPINRAZA in infants and children with spinal muscular atrophy (SMA) who have unmet clinical needs after Zolgensma treatment. The study aims to include 60 participants, with a focus on those exhibiting suboptimal motor function. Previous studies indicated that 4 out of 10 patients treated with Zolgensma proceeded to SPINRAZA. Biogen's ongoing commitment involves generating data to enhance treatment decisions for SMA patients.
On July 13, 2020, the Alzheimer's Clinical Trials Consortium (ACTC), Eisai, and Biogen announced the initiation of a new Phase III study, AHEAD 3-45, for BAN2401, an anti-amyloid beta antibody. This study aims to address preclinical Alzheimer's disease in over 1400 participants across multiple countries, focusing on early intervention to prevent cognitive decline. The study will utilize a rigorous endpoint evaluation, including amyloid and tau PET imaging and cognitive assessments. Results from this trial could provide valuable insights on the timing of anti-amyloid therapy interventions.
Biogen announced positive results from a Phase 1/2 study of tofersen (BIIB067), targeting SOD1 amyotrophic lateral sclerosis (ALS). The study, published in The New England Journal of Medicine, showed proof-of-concept, demonstrating a 36% reduction in SOD1 protein concentration in treated patients. Serious adverse events occurred, including two deaths in the tofersen group. Biogen emphasizes its commitment to ALS research despite past challenges. A Phase 3 study, VALOR, is currently underway to further assess tofersen's efficacy and safety.
FAQ
What is the current stock price of Biogen (BIIB)?
What is the market cap of Biogen (BIIB)?
What does Biogen Inc. specialize in?
Where is Biogen headquartered?
What are some of Biogen's key products?
How many employees does Biogen have?
What recent acquisitions has Biogen made?
What are Biogen’s latest research initiatives?
How is Biogen improving travel for people with mobility issues?
What is Biogen’s approach to corporate responsibility?
What is Leqembi and what is its significance?
Where can I find more information about Biogen?
